Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
Recruiting · NCT07492927 · Observational (researchers observe without assigning treatment) · Lead sponsor: Xijing Hospital
View the official record on ClinicalTrials.gov →What this trial is about
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Blood prostate-specific antigen PSA\>4ng/dl;
- Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging.
- The patient is willing to undergo prostate biopsy.
Exclusion criteria
- Previous diagnosis of prostate cancer through prostate biopsy;
- History of other malignant tumors in the past two years;
- According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment
Where it is running
10 locations listed across 1 US state.
- Northwestern Memorial Hospital - Chicago, Illinois, United States
- Xijing Hospital - Xi'an, China
- The First Hospital of Lanzhou University - Lanzhou, Gansu, China
- General Hospital of Ningxia Medical University - Yinchuan, Ningxia, China
- Qinghai University Affiliated Hospital - Xining, Qinghai, China
- Weinan Central Hospital - Weinan, Shaanxi, China
- Shaanxi Provincial People's Hospital - Xi'an, Shaanxi, China
- Xijing 986 Hospital - Xi'an, Shaanxi, China
- The Second Affiliated Hospital of Shaanxi University of Chinese Medicine - Xianyang, Shaanxi, China
- Yan'an University Affiliated Hospital - Yan’an, Shaanxi, China